Association of Breast Cancer Subtypes and Body Mass Index

Petekkaya, İbrahim; Şahin, Uğur; Gezgen, Gamze; Solak, Mustafa; Yüce, Deniz; Dizdar, Ömer; Arslan, Çağatay; Ayyildiz, Veysel; Altundağ, Kadri̇

doi:10.1177/030089161309900201

Cited by 11 publications

(7 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, these associations were not statistically significant [30]. Some other studies suggested that the association between BMI and an increased risk of breast cancer might be limited to pre-menopausal hormone receptor-negative breast cancer [31–32]. This suggests that the association between BMI and cancer varies by cancer subtype, which warrants future studies.…”

Section: Discussionmentioning

confidence: 99%

BMI and Lifetime Changes in BMI and Cancer Mortality Risk

et al. 2015

View full text Add to dashboard Cite

Body Mass Index (BMI) is known to be associated with cancer mortality, but little is known about the link between lifetime changes in BMI and cancer mortality in both males and females. We studied the association of BMI measurements (at baseline, highest and lowest BMI during the study-period) and lifetime changes in BMI (calculated over different time periods (i.e. short time period: annual change in BMI between successive surveys, long time period: annual change in BMI over the entire study period) with mortality from any cancer, and lung, colorectal, prostate and breast cancer in a large cohort study (n=8,645. Vlagtwedde-Vlaardingen, 1965-1990) with a follow-up on mortality status on December 31st 2008. We used multivariate Cox regression models with adjustments for age, smoking, sex, and place of residence. Being overweight at baseline was associated with a higher risk of prostate cancer mortality (hazard ratio (HR) =2.22; 95% CI 1.19-4.17). Obesity at baseline was associated with a higher risk of any cancer mortality [all subjects (1.23 (1.01-1.50)), and females (1.40 (1.07-1.84))]. Chronically obese females (females who were obese during the entire study-period) had a higher risk of mortality from any cancer (2.16 (1.47-3.18), lung (3.22 (1.06-9.76)), colorectal (4.32 (1.53-12.20)), and breast cancer (2.52 (1.15-5.54)). We found no significant association between long-term annual change in BMI and cancer mortality risk. Both short-term annual increase and decrease in BMI were associated with a lower mortality risk from any cancer [all subjects: (0.67 (0.47-0.94)) and (0.73 (0.55-0.97)), respectively]. In conclusion, a higher BMI is associated with a higher cancer mortality risk. This study is the first to show that short-term annual changes in BMI were associated with lower mortality from any type of cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

BMI and Lifetime Changes in BMI and Cancer Mortality Risk

et al. 2015

View full text Add to dashboard Cite

show abstract

“…Hence, joint detection of tumor markers is of great importance in the early discovery and treatment of patients as well as the judgment on progression and prognosis of disease. The previous studies revealed that the prognosis of patients with breast cancer who had both negative estrogen receptor (ER) and progesterone receptor (PR) was very poor, suggesting that detection of ER and PR expression plays a key role in judging the prognosis of disease (Patel et al, 2013;Petekkaya et al, 2013). Vascular endothelial growth factor (VEGF) capable of promoting angiogenesis exerts an important effect in the process of genesis, development, metastasis and recurrence of various tumors.…”

Section: Introductionmentioning

confidence: 99%

Expression and Significance of ER, PR, VEGF, CA15-3, CA125 and CEA in Judging the Prognosis of Breast Cancer

Zhang

Hu²,

Qian³

et al. 2013

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Objective: To explore the expression and significance of estrogen receptor (ER), progestrone receptor (PR), vascular endothelial growth factor (VEGF), CA15-3, CA125 and carcinoma embryonic antigen (CEA) expression in judging the prognosis of breast cancer. Materials and Methods: Sixty-five patients with breast cancer undergoing operations in the general surgery department were considered as the observation group, and 50 healthy outpatients of our hospital as the control group. Cubital venous blood was drawn in the morning from fasting patients in the two groups and chemiluminescence immunoassays were used to detect the levels of CA15-3, CA125 and CEA in serum. The follow-up duration was from 4 months to 2 years, and change in levels of the indicators was detected by dynamically drawing blood. After surgery, cancer tissue samples of patients in observation group remained on file (the non-recurrent patients were biopsied). Immunohistochemistry was applied to determine the expression of ER, PR and VEGF in tissue. Results: The effective rate of 12 patients with negative ER and PR expression was 33.3% in the observation group, being associated with prognosis to varying extents. Serum CA15-3, CA125 and CEA in the observation group were all significantly higher than in control group (p<0.01). With increase in pathological staging, levels of serum CA15-3, CA125 and CEA gradually increased (p<0.01). Levels in patients with lymph node metastasis were markedly higher than in those without (p<0.01). In addition, values with distal lymph node metastasis were notably higher than with adjacent lymph node metastasis (p<0.01). The postoperative follow-up results revealed that positive VEGF and levels of serum VEGF, CA15-3, CA125 and CEA in recurrence group were obviously higher than in non-recurrence group (p<0.01). Conclusions: Joint detection of ER and PR expression as well as levels of serum VEGF, CA15-3, CA125 and CEA is meaningful and can guide the diagnosis and treatment for breast cancer.

show abstract

“…The Public around the world paying attention to the prevalence of Obesity 1 due to its association with chronic diseases like breast cancer 2 , COPD 3 and soon. In human beings serum Uric acid is end product of purine metabolism 4 .…”

Section: Introductionmentioning

confidence: 99%